A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced Solid Tumor
In brief
This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-XT117 injection in patients with FAP-positive advanced solid tumors. Dose escalation will be conducted to determine the Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D), and to assess dosimetry characteristics.
Key facts
- Study ID
- NCT06211647
- Run by
- Ruimin Wang
- People needed
- 20
- Starts
- 2024-01-01
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2024-01-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The First Medical Center, Chinese PLA General Hospital — Beijing, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.